{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:02:03Z","timestamp":1762254123782,"version":"3.37.3"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In the current study, we examined the real-world prevalence of highly pigmented advanced melanomas (HPMel) and the clinicopathologic, genomic, and ICPI biomarker signatures of this class of tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Our case archive of clinical melanoma samples for which the ordering physician requested testing for both PD-L1 immunohistochemistry (IHC) and comprehensive genomic profiling (CGP) was screened for HPMel cases, as well as for non-pigmented or lightly pigmented advanced melanoma cases (LPMel).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 1268 consecutive melanoma biopsies in our archive that had been submitted for PD-L1 IHC, 13.0% (165\/1268) were HPMel and 87.0% (1103\/1268) were LPMel. In the HPMel cohort, we saw a significantly lower tumor mutational burden (TMB, median 8.8 mutations\/Mb) than in the LPMel group (11.4 mut\/Mb), although there was substantial overlap. In examining characteristic secondary genomic alterations (GA), we found that the frequencies of GA in TERTp, CDKN2A, TP53, and PTEN were significantly lower in the HPMel cases than in LPMel. A higher rate of GA in CTNNB1, APC, PRKAR1A, and KIT was identified in the HPMel cohort compared with LPMel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this study, we quantified the failure rates of melanoma samples for PD-L1 testing due to high melanin pigmentation and showed that CGP can be used in these patients to identify biomarkers that can guide treatment decisions for HPMel patients. Using this practical clinical definition for tumor pigmentation, our results indicate that HPMel are frequent at 13% of melanoma samples, and in general appear molecularly less developed, with a lower TMB and less frequent secondary GA of melanoma progression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac090","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T19:19:31Z","timestamp":1650050371000},"page":"655-662","source":"Crossref","is-referenced-by-count":4,"title":["Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8395-5168","authenticated-orcid":false,"given":"Richard S P","family":"Huang","sequence":"first","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie Y","family":"Tse","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Harries","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryon P","family":"Graf","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas I","family":"Lin","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthikeyan","family":"Murugesan","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew C","family":"Hiemenz","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamsi","family":"Parimi","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Janovitz","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brennan","family":"Decker","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Severson","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia A","family":"Levy","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"},{"name":"Rush University Medical Center , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakti H","family":"Ramkissoon","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"},{"name":"Wake Forest Comprehensive Cancer Center, and Department of Pathology, Wake Forest School of Medicine , Winston-Salem, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia A","family":"Elvin","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"},{"name":"Department of Pathology, State University of New York (SUNY) Upstate Medical University , Syracuse, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik A","family":"Williams","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc ., Cambridge, MA , USA"},{"name":"Department of Pathology, Department of Dermatology, UCSF Dermatopathology Service, University of California San Francisco , San Francisco, CA , USA"},{"name":"Department of Pathology and Laboratory Medicine, University of Miami, Sylvester Comprehensive Cancer Center, and Jackson Memorial Hospitals , Miami, FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"author":"Society AC.","key":"2022080911502196400_CIT0001"},{"issue":"1","key":"2022080911502196400_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9010223","article-title":"Anti-PD-1 and novel combinations in the treatment of melanoma-an update","volume":"9","author":"Gellrich","year":"2020","journal-title":"J Clin Med"},{"issue":"4","key":"2022080911502196400_CIT0003","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"2022080911502196400_CIT0004","article-title":"Abstract CT001: durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial","volume":"76","author":"Hodi","year":"2016","journal-title":"Cancer Res"},{"issue":"9948","key":"2022080911502196400_CIT0005","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"2022080911502196400_CIT0006","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"author":"Administration. FaD.","key":"2022080911502196400_CIT0007"},{"issue":"2","key":"2022080911502196400_CIT0008","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41379-020-00664-y","article-title":"A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases","volume":"34","author":"Huang","year":"2021","journal-title":"Mod Pathol"},{"author":"FDA.","key":"2022080911502196400_CIT0009"},{"author":"FDA.","key":"2022080911502196400_CIT0010"},{"issue":"9","key":"2022080911502196400_CIT0011","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","article-title":"Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"2022080911502196400_CIT0012","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.annonc.2020.02.017","article-title":"Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer","volume":"31","author":"Lamberti","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"2022080911502196400_CIT0013","doi-asserted-by":"crossref","first-page":"e2011818","DOI":"10.1001\/jamanetworkopen.2020.11818","article-title":"Evaluation of programmed death ligand 1 (PD-L1) gene amplification and response to nivolumab monotherapy in non-small cell lung cancer","volume":"3","author":"Inoue","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2022080911502196400_CIT0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2021-002680","article-title":"Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression","volume":"9","author":"Huang","year":"2021","journal-title":"J ImmunoTher Cancer"},{"issue":"15","key":"2022080911502196400_CIT0015","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2022080911502196400_CIT0016","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ctrv.2018.07.006","article-title":"Hyperprogression as a distinct outcome after immunotherapy","volume":"70","author":"Fuentes-Antr\u00e1s","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"2022080911502196400_CIT0017","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"2022080911502196400_CIT0018","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.annonc.2020.08.2105","article-title":"KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden","volume":"31","author":"Marinelli","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"2022080911502196400_CIT0019","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/onco.13753","article-title":"Clinicopathologic and genomic characterization of PD-L1 positive urothelial carcinomas","volume":"26","author":"Huang","year":"2021","journal-title":"Oncologist"},{"issue":"7","key":"2022080911502196400_CIT0020","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41379-021-00780-3","article-title":"Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma","volume":"34","author":"Huang","year":"2021","journal-title":"Mod Pathol"},{"issue":"1","key":"2022080911502196400_CIT0021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41698-020-0112-3","article-title":"PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer","volume":"4","author":"Zhou","year":"2020","journal-title":"NPJ Precis Oncol"},{"issue":"11","key":"2022080911502196400_CIT0022","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jamaoncol.2019.3158","article-title":"Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma","volume":"5","author":"Braun","year":"2019","journal-title":"JAMA Oncol"},{"issue":"11","key":"2022080911502196400_CIT0023","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2022080911502196400_CIT0024","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"issue":"6","key":"2022080911502196400_CIT0025","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diagn"},{"issue":"13 Suppl","key":"2022080911502196400_CIT0026","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1158\/1538-7445.AM2019-1599","article-title":"Abstract 1599: determining patient ancestry based on targeted tumor comprehensive genomic profiling","volume":"79","author":"Newberg","year":"2019","journal-title":"Cancer Res"},{"issue":"5","key":"2022080911502196400_CIT0027","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2020.04.012","article-title":"Comprehensive analysis of genetic ancestry and its molecular correlates in cancer","volume":"37","author":"Carrot-Zhang","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"2022080911502196400_CIT0028","doi-asserted-by":"crossref","first-page":"e216481","DOI":"10.1001\/jamanetworkopen.2021.6481","article-title":"Prevalence of high-risk nonvaccine human papillomavirus types in advanced squamous cell carcinoma among individuals of African vs non-African ancestry","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2022080911502196400_CIT0029","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"20","key":"2022080911502196400_CIT0030","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2022080911502196400_CIT0031","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"2022080911502196400_CIT0032","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jaad.2020.07.050","article-title":"Clinical, histopathologic, and molecular profiles of PRKAR1A-inactivated melanocytic neoplasms","volume":"84","author":"Williams","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2022080911502196400_CIT0033","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/DAD.0000000000001185","article-title":"Heavily pigmented epithelioid melanoma with loss of protein kinase A regulatory subunit-\u03b1 expression","volume":"40","author":"Cohen","year":"2018","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"2022080911502196400_CIT0034","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41467-017-00758-3","article-title":"Combined activation of MAP kinase pathway and \u03b2-catenin signaling cause deep penetrating nevi","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"2022080911502196400_CIT0035","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/PAS.0000000000001458","article-title":"Genomic and clinicopathologic characteristics of PRKAR1A-inactivated melanomas: toward genetic distinctions of animal-type melanoma\/pigment synthesizing melanoma","volume":"44","author":"Cohen","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2022080911502196400_CIT0036","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1309\/DVWLTV8FFKC3L80H","article-title":"Anorectal malignant melanoma: morphologic and immunohistochemical features","volume":"126","author":"Chute","year":"2006","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"2022080911502196400_CIT0037","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/modpathol.2013.211","article-title":"Comparison of molecular abnormalities in vulvar and vaginal melanomas","volume":"27","author":"Aulmann","year":"2014","journal-title":"Mod Pathol"},{"issue":"8","key":"2022080911502196400_CIT0038","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cyto.a.20319","article-title":"Multispectral imaging in biology and medicine: slices of life","volume":"69","author":"Levenson","year":"2006","journal-title":"Cytometry A"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/8\/655\/45293596\/oyac090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/8\/655\/45293596\/oyac090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T11:51:12Z","timestamp":1660045872000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/8\/655\/6584945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,12]]},"published-print":{"date-parts":[[2022,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac090","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,12]]}}}